Frag 176-191 & Mod GRF 1-29 & Ipamorelin Blend Actions on Adipose Cells

Frag 176-191, Mod GRF 1-29, and Ipamorelin are peptides that researchers believe may impact the metabolism of fat cells through several different mechanisms. For example, Fragment 176-191 is typically characterized as a synthetic peptide derived from the C-terminal segment of growth hormone (hGH).

On the other hand, Mod GRF 1-29 & Ipamorelin are peptides purported to work by impacting the synthesis of the complete hGH molecule by pituitary gland cells. Here is what researchers should know about each of the constituents in this blend:

• Frag 176-191 comprises the GH residues numbered 176–191, typically replacing the first amino acid with a tyrosine residue at the N-terminal end.⁽¹⁾ This 16 amino acid peptide reportedly retains the disulfide bond between cysteine residues at positions analogous to Cys182 and Cys189 in the intact hGH molecule, corresponding to positions 7 and 14 within the peptide. The conserved disulfide bridge and the added N-terminal tyrosine are hypothesized to support peptide stability and bioavailability, possibly offering resistance to harsh pH conditions and enzymatic degradation. Frag 176-191 is thought to mimic GH’s lipolytic (fat-breaking) potential while seemingly not affecting carbohydrate metabolism, insulin-like growth factor-1 (IGF-1) synthesis, or cellular proliferation. ⁽²⁾ It may also interact with alternative receptors such as the β3-adrenergic receptor.
• Modified GRF 1-29 is commonly described as a synthetic analog derived from the first 29 amino acids of the endogenous Growth Hormone Releasing Hormone (GHRH).⁽³⁾ As such, it may interact with the GHRH receptors, Modified GRF 1-29 on pituitary gland cells, and impact hGH synthesis. It is termed “modified” or Mod GRF 1-29 as it reportedly differs from endogenous GHRH by specific amino acid substitutions at positions 2, 8, 15, and 27. Specifically, the substitutions at the 2nd, 15th, and 27th positions may help the peptide resist being broken down by enzymes and extend its half-life. Additionally, alterations such as the lysine substitution at position 8 may improve receptor-binding affinity. Mod GRF 1-29 is thought to retain, and perhaps even surpass, the GHRH’s ability to stimulate hGH secretion.
• Ipamorelin, also believed by its experimental identifier NNC 26-0161, is a pentapeptide characterized by the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, which also interacts with the pituitary gland cells but via a different mechanism.⁽⁴⁾ It is categorized among Growth Hormone Secretagogues (GHS), it appears to selectively stimulate hGH synthesis by influencing the GHS receptors, also believed to be ghrelin receptors, in pituitary gland cells. Ipamorelin appears to stand out with its selectivity towards hGH, while other GHSs may also interfere with cortisol or prolactin secretion.

 

Research

Frag 176-191 & Mod GRF 1-29 & Ipamorelin Blend Interactions with Pituitary Receptors

While the primary research focus of the Frag 176-191 blend, Mod GRF 1-29, and Ipamorelin involves fat cells, their potential impact on adipocyte cultures goes through a multistep process involving interactions with receptors located on pituitary cells. Specifically, Mod GRF 1-29 and Ipamorelin appear to be the peptides within this combination that might directly engage these receptors to impact hGH synthesis. A review by Sinha et al. suggests that Mod GRF 1-29 potentially interacts with GHRH receptors found on anterior pituitary cells. ⁽⁵⁾

Interactions like these might initiate intracellular signaling cascades and may ultimately support hGH synthesis. One proposed intracellular pathway involves the enzyme adenylyl cyclase, which is hypothesized to convert adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). The increased levels of cAMP may activate protein kinase A (PKA), an enzyme potentially responsible for phosphorylating various cellular proteins. Such phosphorylation might affect proteins like voltage-dependent calcium channels on pituitary cell membranes, possibly resulting in channel opening, calcium influx, and subsequent release of growth hormone from secretory vesicles.

A separate study conducted by Alba et al. suggested that the peptide Mod GRF (1-29) may elevate the total amount of RNA within the pituitary gland and specifically increase the messenger RNA (mRNA) levels responsible for encoding growth hormone.⁽⁶⁾ Such findings might reflect an increase in somatotroph cell populations—the specialized pituitary cells primarily associated with synthesizing and releasing growth hormone. Researchers posited that the peptide “caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images.” Conversely, Ipamorelin might preferentially target a distinct class of receptors believed to be growth hormone secretagogue receptor 1a (GHS-R1a), commonly called ghrelin receptors, which endogenously respond to the hormone ghrelin, according to research by Jiménez-Reina et al. Ipamorelin binding to these receptors may induce subtle receptor conformational changes, potentially activating complex intracellular signaling pathways.

Within these pathways, phospholipase C (PLC) is speculated to play a critical role by potentially catalyzing the formation of second messengers, such as inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 might stimulate the controlled release of calcium ions (Ca²⁺) from intracellular storage compartments if formed. In contrast, DAG may activate protein kinase C (PKC), an enzyme family that modulates diverse cellular functions. Elevated intracellular calcium and possible PKC activation may collectively impact gene transcription events, presumably supporting growth hormone synthesis and secretion. However, the precise molecular details require further experimental clarification.

Frag 176-191 & Mod GRF 1-29 & Ipamorelin Blend Interactions with Adrenergic Receptors

Unlike Mod GRF 1-29 and Ipamorelin, Frag 176-191 interacts directly with adipocytes, potentially mimicking the fat breakdown capabilities of the full-length hGH molecule. Research by Ng et al. suggests these actions might involve the activation of hormone-sensitive lipase (HSL), an enzyme critical for hydrolyzing stored triglycerides into free fatty acids and glycerol, possibly mitigating adipocyte size.⁽⁸⁾ Additionally, Frag 176-191 may inhibit acetyl-CoA carboxylase, an enzyme associated with fatty acid synthesis, potentially limiting new adipose accumulation.

Further investigations by Ng et al. have proposed that the impacts of Frag 176-191 on enzymes such as HSL and acetyl-CoA carboxylase may be linked to intracellular signaling mechanisms involving the biphasic release of DAG, similar to that observed with GH.⁽⁹⁾ This DAG release might activate protein kinase C, followed by activating enzymes such as HSL, which facilitate the breakdown of stored triglycerides into free fatty acids and glycerol. In addition to direct lipolytic potential, Frag 176-191 might indirectly support energy expenditure, possibly through potential modulation of β3-adrenergic receptor (β3-AR) expression. These are thought to be some of the key receptors that promote lipolysis in adipose cells.

Research by Hefferman et al. suggests Frag 176-191 may increase adipocyte sensitivity to lipolytic signals by influencing β3-AR mRNA expression levels.⁽¹⁰⁾ Studies conducted while observing research models impacted by obesity indicate that Frag 176-191 experimentation may restore mitigated β3-AR levels to those similar to control models. This observation suggests that Frag 176-191 might elevate levels of these receptors in adipocytes. This may support the cells’ responsiveness to catecholamines, hormones promoting lipolysis.

Frag 176-191 & Mod GRF 1-29 & Ipamorelin Blend Interactions with Lipolysis in Adipocytes

Overall, researchers have proposed that Mod GRF (1-29) and Ipamorelin may impact adipose tissue indirectly through modulation of growth hormone (GH) secretion. On the other hand, Fragment 176-191 (Frag 176-191) might interact directly with adipocyte cells. By potentially increasing systemic GH levels, Mod GRF (1-29) and Ipamorelin may impact adipocyte metabolism, as GH is widely recognized for its ability to stimulate lipolysis, particularly within visceral fat stores. Dehkhoda et al. suggest that “GH impacts adipose tissue in a depot-specific manner and impacts other features of adipose tissue (for example, senescence, adipocyte subpopulations, and fibrosis), all of which [may] impact lipolysis.”⁽¹¹⁾ This depot-specific impact might result from a higher density of GH receptors in visceral adipocytes relative to subcutaneous adipocytes.

With all this in mind, it is expected that Frag 176-191 may also have depot-specific preferences on adipocytes. Regardless, the aforementioned research by Ng et al. observed that Frag 176-191 might support lipolytic activity by approximately 23%, suggesting a significant overall potential.⁽⁸⁾ Additionally, the researchers suggested that this peptide may mitigate adipose tissue accumulation by over 50% in research models. These researchers proposed that their findings indicate, possibly for the first time, the capability of this synthetic lipolytic segment to mitigate elevations in mass and adipose stores in laboratory settings. The aforementioned research by Hefferman et al has also indicated that Frag 176-191 may substantially support fatty acid oxidation rates, particularly noted in models of obesity, where fat oxidation reportedly increased by as much as 216%.⁽¹⁰⁾

The impact of Ipamorelin may extend beyond GH release, as studies by Lall et al. suggest that this peptide also interacts with ghrelin receptors located within the nervous system, potentially promoting signals associated with an observable elevation in hunger hormone signaling.⁽¹²⁾ This better-supported ghrelin-mediated signaling may have the potential to lead to greater caloric consumption and subsequent fat accumulation primarily in subcutaneous depots. Since subcutaneous adipocytes typically display lower densities of GH receptors than visceral adipocytes, they may not respond as well to GH-induced or Frag 176-191-mediated lipolysis, possibly resulting in differential regional adipose mobilization.

Frag 176-191 & Mod GRF 1-29 & Ipamorelin Blend Synergistic Potential

The differences in the interactions of peptides like Mod GRF (1-29) and Ipamorelin with pituitary cells have led some investigators to propose a potential synergistic impact when these compounds are exposed to research models concurrently. Specifically, the hypothesis suggests that the simultaneous exposure of both peptide types—Mod GRF (a growth hormone-releasing hormone (GHRH) analog) and Ipamorelin (a growth hormone secretagogue receptor (GHS-R) agonist)—may lead to better-supported stimulation of growth hormone secretion. Results may be observed exceeding the results that each peptide might independently achieve.

The aforementioned literature review by Sinha et al. further supports this idea by highlighting preliminary findings wherein GHRH analogs and GHS-R agonists applied separately appeared to elevate pulsatile GH secretion, with reports indicating approximately 20-fold and 47-fold increases above baseline.⁽⁵⁾ Interestingly, combining these two agents within laboratory environments reportedly resulted in an even more pronounced increase, approximately a 54-fold elevation in pulsatile GH secretion compared to baseline conditions.

Data collected in laboratory settings by Khorram et al. suggests Mod GRF (1-29) alone might support growth hormone secretion by approximately 70% to 107% compared to controls.⁽¹³⁾ Meanwhile, Gobburu et al. reported that Ipamorelin may potentially elevate growth hormone concentrations up to around 80 mIU/L (equivalent to roughly 27 nanograms per milliliter), representing approximately a 60-fold increase relative to placebo-exposed samples in laboratory conditions.⁽¹⁴⁾ However, direct experimental data evaluating the combined implication of Mod GRF (1-29) and Ipamorelin is currently lacking. Research has not yet assessed how incorporating Frag 176-191 might further impact or complement the potential combined impacts of these peptides.

You can find Frag 176-191 & Mod GRF 1-29 & Ipamorelin blend for sale with 99% purity, on our website (available for research use only).

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. Isidro ML, Cordido F. Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options. Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145. doi: 10.3390/ph3010125. PMID: 27713245; PMCID: PMC3991023.
2. Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015 Jan;7(1):31-8. doi: 10.1002/dta.1715. Epub 2014 Sep 10. PMID: 25208511.
3. Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058. https://doi.org/10.1210/en.2004-1286
4. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
5. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in modern body composition management in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
6. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
7. Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. impact of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707-14. doi: 10.14670/HH-17.707. PMID: 12168778.
8. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.
9. Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000 Dec;25(3):287-98. doi: 10.1677/jme.0.0250287. PMID: 11116208.
10. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1442-9. doi: 10.1038/sj.ijo.0801740. PMID: 11673763.
11. Dehkhoda F, Lee CMM, Medina J, Brooks AJ. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects. Front Endocrinol (Lausanne). 2018 Feb 13;9:35. doi: 10.3389/fendo.2018.00035. PMID: 29487568; PMCID: PMC5816795.
12. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001 Jan 12;280(1):132-8. doi: 10.1006/bbrc.2000.4065. PMID: 11162489.
13. Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
14. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6. doi: 10.1023/a:1018955126402. PMID: 10496658.